Specifically, FOXK2 was found to be significantly overexpressed in tumor tissues of prostate adenocarcinoma (PRAD), endometrial cancer (UCEC), BLCA, CRC, pancreatic duct adenocarcinoma (PDAC), STAD, lung cancer, and thyroid cancer. This evidence concerns the gene FOXK2 and thyroid gland carcinoma.